Literature DB >> 6284652

Mecillinam alone and in combination with ampicillin or moxalactam in experimental Escherichia coli meningitis.

U B Schaad, L M Grimm, G Beskid, R Cleeland, J D Nelson, G H McCracken.   

Abstract

The activity of mecillinam, ampicillin and moxalactam alone and in combination was determined in a lapin meningitis model and a mouse meningitis model against two Escherichia coli strains isolated from infants with meningitis. Both strains were highly susceptible in vitro to the antibiotics, and responded well in systemic mouse protection tests (PD50 less than 4 mg/kg). Continuous infusion of mecillinam in the lapin model over nine hours was effective in sterilizing the CSF of three of four animals infected with one strain. This prompt bacteriologic response to mecillinam alone precluded the possibility of constant infusion administration for synergy studies. Therefore, single dose administration was used to demonstrate the synergistic potential of mecillinam with ampicillin in the lapin meningitis model against the E. coli Kl # 2 strain. The combination of moxalactam and mecillinam was synergistic against the E. coli Kl # 2 strain in the mouse meningitis model. The synergistic potential of these combinations could not be reliably predicted by in vitro tests, time kill curves or systemic mouse protection tests.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284652     DOI: 10.1007/bf01816731

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  22 in total

1.  An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics.

Authors:  E STEERS; E L FOLTZ; B S GRAVES
Journal:  Antibiot Chemother (Northfield)       Date:  1959-05

2.  Inhibition of an early event in the cell division cycle of Escherichia coli by FL1060, an amidinopenicillanic acid.

Authors:  R James; J Y Haga; A B Pardee
Journal:  J Bacteriol       Date:  1975-06       Impact factor: 3.490

3.  The mechanism of action of mecillinam.

Authors:  B G Spratt
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

4.  Agar plate dilution method for routine antibiotic susceptibility testing in a hospital laboratory.

Authors:  K C Haltalin; A H Markley; E Woodman
Journal:  Am J Clin Pathol       Date:  1973-09       Impact factor: 2.493

5.  Antimicrobial synergism--an elusive concept.

Authors:  R C Moellering
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

6.  Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: bactericidal action and synergy in vitro.

Authors:  L Tybring; N H Melchior
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

7.  A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group.

Authors:  G H McCracken; S G Mize
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

8.  Synergy of mecillinam, a beta-amidinopenicillanic acid derivative, combined with beta-lactam antibiotics.

Authors:  J C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

9.  Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

10.  Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.

Authors:  U B Schaad; G H McCracken; N Threlkeld; M L Thomas
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

View more
  2 in total

1.  Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals.

Authors:  N Klesel; M Limbert; E Schrinner; K Seeger; G Seibert; I Winkler
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

Review 2.  Rationale for optimal dosing of beta-lactam antibiotics in therapy for bacterial meningitis.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.